Table 1 Baseline clinical characteristics of study patients according to implant technique
Characteristics | Total sample | Implant technique | P value | |
|---|---|---|---|---|
PP | IoP | |||
(n =1176) | (n =132) | (n = 1044) | ||
Age, years | ||||
Mean (SD) | 66.2 (6.5) | 67.8 (5.9) | 66.0 (6.5) | |
Median | 67.0 | 68.0 | 67.0 | |
Range | 45.0–80.0 | 50.0–79.0 | 45.0–80.0 | |
95% CI | 65.9–66.6 | 66.8–68.8 | 65.6–66.4 | 0.002* |
PSA, ng/ml | ||||
Mean (SD) | 7.4 (3.1) | 8.6 (3.8) | 7.2 (3.0) | |
Median | 6.7 | 7.6 | 6.6 | |
Range | 0.6–22.0 | 0.7–20.0 | 0.6–22.0 | |
95% CI | 7.2–7.6 | 7.9–9.2 | 7.1–7.4 | <0.001* |
PSA, n (%) | ||||
≤ 10 | 980 (83.3) | 94 (71.2) | 886 (84.9) | |
> 10 | 196 (16.7) | 38 (28.8) | 158 (15.1) | <0.001** |
Gleason score, | ||||
Mean (SD) | 5.9 (0.6) | 5.3 (0.8) | 6.0 (0.5) | |
Median | 6.0 | 5.0 | 6.0 | |
Range | 3.0–7.0 | 3.0–7.0 | 3.0–7.0 | |
95% CI | 5.91–5.98 | 5.2–5.5 | 5.9–6.1 | <0.001* |
Gleason score < 7, n (%) | 1044 (88.8) | 128 (97.0) | 916 (87.7) | 0.002** |
Prostate volume, ml | ||||
Mean (SD) | 38.4 (9.6) | 35.0 (9.1) | 38.8 (9.6) | |
Median | 38.0 | 35.0 | 39.0 | |
Range | 10.0–74.0 | 13.0–57.0 | 10.0–74.0 | |
95% CI | 37.8–68.9 | 33.4–36.6 | 38.2–39.4 | <0.001* |
Clinical stage, n (%) | ||||
T1-T2a | 1086 (92.3) | 113 (85.6) | 973 (93.2) | |
> T2a | 56 (4.8) | 14 (10.6) | 42 (4.0) | 0.001** |
ADT, n (%) | 442 (37.6) | 54 (40.9) | 388 (37.2) | 0.4** |
EBRT, n (%) | 132 (11.2) | 4 (3) | 128 (12.3) | 0.002** |
Follow-up, months | ||||
Mean (SD) | 51.8 (35.1) | 80.5 (43.5) | 48.1 (32.1) | |
Median | 47.0 | 83.0 | 47.0 | |
Range | 1.0–155.0 | 3.0–155.0 | 1.0–132.0 | |
95% CI | 49.7–53.8 | 72.9–87.9 | 46.2–50.1 | <0.001* |